Home
About
Product
News
Honor
Contact
Purchasing
Company News
Industry trends
Purchasing information
2017-07-21
Today, the company announced that it signed the Third Amendment with the existing shareholders and related parties of India Gland, adjusting the transaction to: the company invested no more than US $1091.3 million to acquire about 74% of Gland's equity, including the contingent consideration paid for the listing and sale of Gland Enoxaparin in the United States, which did not exceed US $25 million. The termination date of this transaction is extended to October 3, 2017.
2017-09-20
Exploring the Sweet Side of Anhydrous Sodium Saccharin in Various Industries
2025-12-29
The Sweet Science Behind Anhydrous Sodium Saccharin
2025-12-26
Sweet Success: Industry Case Studies on Saccharin Sodium
2025-12-23
The Sweet Science Behind Saccharin Sodium: Unpacking the Myths and Facts
2025-12-20
Bilirubin: The Unsung Hero of Industry Insights
2025-12-17
Bilirubin: The Unsung Hero of Your Health
2025-12-14